A Look At Bicara Therapeutics (BCAX) Valuation After New FICERA Clinical Data And Accelerated Approval Plan [Yahoo! Finance]
Bicara Therapeutics Inc. (BCAX)
Company Research
Source: Yahoo! Finance
Bicara Therapeutics (BCAX) is back on investors' radar after reporting clinical data for its FICERA program, which showed a 54% overall response rate and a 21% complete response rate, along with plans to pursue accelerated approval. See our latest analysis for Bicara Therapeutics. At a share price of $18.47, Bicara's recent FICERA update and the completed roughly US$150m follow on offering appear to be drawing attention. The 7 day share price return of 10.07% and 1 year total shareholder return of 11.60% suggest that momentum has picked up again after a quieter few months. If FICERA's progress has you looking more closely at oncology and immunology, it could be a good moment to widen your search with our screen of 32 healthcare AI stocks and see what else is emerging in this space. With Bicara now trading at $18.47 and screens suggesting a sizable gap to some valuation estimates, the real question is whether FICERA's promise is still underappreciated or if the market is alrea
Show less
Read more
Impact Snapshot
Event Time:
BCAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCAX alerts
High impacting Bicara Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BCAX
News
- Bicara Therapeutics Talks Ficerasfusp Alfa Data, Pivotal Trial Timeline and $172M Raise at Conference [Yahoo! Finance]Yahoo! Finance
- Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswire
- Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswire
BCAX
Earnings
- 11/10/25 - Miss
BCAX
Sec Filings
- 3/11/26 - Form 4
- 3/9/26 - Form 144
- 3/6/26 - Form 4
- BCAX's page on the SEC website